Commercial Insight: Inflammatory Bowel Disease - Convenience And Compliance Drive Market Success

By Author: Manjula Menon
Total Articles: 1486
Comment this article

Several product launches and indication expansion caused substantial sales growth in the seven major inflammatory bowel disease markets from $1.7 billion in 2004 to $2.7 billion in 2007. It forecasts the IBD market will grow with a CAGR (200717) of 4.6% to reach $4 billion in 2017 and success will depend on brands demonstrating patient convenience and improved compliance.

Scope of this report

In-depth analysis of the current and future inflammatory bowel disease market across the US, 5 EU and Japanese markets, and a rest of world snapshot

Crohn's disease and ulcerative colitis specific sales forecasts for key brands to 2017, with total brand figures to benchmark IBD sales against

Provides detailed brand dynamics discussion, including analysis of the anti-TNFs Remicade, Humira, Cimzia and impact of new products such as Tysabri

Assess the strategies of the key developers in the IBD market

Research and analysis highlights

Anti-TNF sales will peak at over $2 billion in 2012 because of earlier use, extension into ulcerative colitis, uptake of Cimzia (certolizumab) and the launch ...
... of golimumab (CNTO-148). Despite competitive pressure from novel agents and biosimilars, the TNF inhibitors will generate $1.8 billion in IBD indications in 2017 and retain market dominance.

Cimzia is the third anti-TNF for Crohn's disease, but with few perceived advantages, it will remain a third-line therapy. Time on the market, method of delivery and patient preference will increasingly determine anti-TNF choice. Humira will attain market and class leadership from Remicade by 2014, achieving IBD sales of $0.8 billion by 2017.

Patient convenience/compliance will drive brand choice in the homogenous 5-ASA class. Lialda reduces pill burden and data indicate superiority to Asacol. With its favorable once-daily dosing, Lialda is set to head the 5-ASA class and smart marketing will minimize Pentasa cannibalization. Lialda will generate total brand sales of over $400 m in 2017

Key reasons to read this report

Quantify the current size of IBD sales in the seven major markets and understand trends in the rest of the world

Assess the impact of events, such as biosimilars entry, on sales of over 30 key brand name products

Understand the IBD patient acquisition process as well as specific market opportunities and threats

For more information Kindly visit the website : http://www.bharatbook.com/detail.asp?id=83043

Or Contact us on :
Tel No : (+9122 )27578668 , 27579438
Fax: (+9122 )27579131

Address :
Bharat Book Bureau,
207,Hermes Atrium,
Sector-11
P.O Box 54,
CBD Belapur,
Navi Mumbai - 400614.